Clinical Trials Logo

Clinical Trial Summary

Diabetes is the leading cause of chronic kidney disease (CKD) and end-stage kidney disease worldwide. Diabetic kidney disease (DKD) is a clinical diagnosis based upon the presence of reduced glomerular filtration rate (GFR) and/or increased urinary albumin excretion (UACR) in diabetes. The inhibition of the renin-angiotensin system (RAS) has been identified as the cornerstone in the management of DKD for decades. Recently, more evidence supports the use of Sodium-glucose cotransporter 2 inhibitors (SGLT2i) in the treatment of DKD. They were associated with slower progression of renal disease and lower rates of clinically relevant kidney events. Those studies confirmed the SGLT2i efficacy in kidney protection and showed that their addition to angiotensin-converting enzyme inhibitors (ACEi) or angiotensin receptor blockers (ARBS) will be more effective than using ACEi or ARBS alone. It is unclear whether SGLT2i is used as a first-line instead of ACEi or ARB, and to what extent it will be effective in managing DKD compared to the proven effect of ACEi/ARBs alone. This study provides a unique opportunity to address this gap in the literature. The aim of this study is to compare, head to head, the renal performance of ACEi (standard of care) versus SGLT2 in diabetic patients who have evidence of deteriorating renal function evidenced by either the reduction of e GFR or increased UACR. Scientific hypotheses: Null hypothesis: after one year, the mean change of the e GFR in the enalapril group - Mean change of the e GFR in the empagliflozin group > or = 5 ml/min/1.73m2 Alternative hypothesis: after one year, the mean change of the e GFR in the enalapril group - Mean change of the e GFR in the empagliflozin group < 5 ml/min/1.73m2


Clinical Trial Description

The gap that could noticeably be found in the available literature is that the studies done on SGLT2i were almost tested on people who already using ACEi or ARBs, thus it is unclear whether SGLT2i is used as a first-line instead of ACEi/ARB (If ACEi/ARB are contraindicated or intolerable), to what extent it will be effective in managing DKD compared to the proven effect of ACEi/ARBs alone? Although there is one subgroup analysis in the CANVAS trial to compare the effect of SGLT2 on patients who are on RAS blockers versus those without RAS blockers, the total number of participants who are not on RAS is very small (around 20%) compared to the total number of participants. the study consists of 2 equal arms, non-inferiority RCT that compares the change in the eGFR rate after one year between the ACEi (enalapril) group versus SGLT2i (empagliflozin) group in 212 men and non-pregnant women with DKD whom age 30-65 years old with UACR above 30mg/g and eGFR ranging from 30-90 ml/min/1.73m2. The study hypothesis is that the mean change of the eGFR in the ACEi group - Mean change of the eGFR in the SGLT2i group is < 5 ml/min/1.73m2 after one year. Results from this study will add to the current literature examining whether the use of SGLT2i, as a first-line or if ACEi is contraindicated or intolerable, is non-inferior to ACEi in preserving kidney function in DKD patients. Superiority could also be declared if present. Further studies with a longer period of time will be required for comparing the long-term effect of both medications on kidneys. Rational: - Based on the ADA/EASD 2019 consensus, SGLT2 inhibitors are recommended in patients with type 2 diabetes in patients with CKD to prevent the progression of CKD (Buse et al.,2019). - The interpretation of the CANVAS subgroup data is that performance of SGLT2i in patients NOT already on RAS inhibitor is good enough that the two 2 equal arms, non-inferiority would be ethically allowable. - Since the existing data are insufficient to be analyzed to extract the answer to this question, "Which is better, an ACEI/ARB or an SGLT2i, to delay the progression of renal impairment?" we already know that the combination is effective but some patients may have a choice to make of one OR the other, this study provides a unique opportunity to tackle this gap in the literature. The reasons beyond the choice of Empagliflozin in this trial were based on many factors. the results of (the EMPA-REG OUTCOME) trial proved its efficacy in delaying the deterioration of kidney function and its availability in the local market. Moreover, it has a good safety profile in comparison to Canagliflozin (ex: risk of bone fracture, lower limb amputation). ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05373004
Study type Interventional
Source Hamad General Hospital
Contact Omar T Elfarargi
Phone 77438042
Email otabdelmoneim@phcc.gov.qa
Status Not yet recruiting
Phase Phase 2/Phase 3
Start date March 2023
Completion date May 2024

See also
  Status Clinical Trial Phase
Terminated NCT03840343 - Patient-Derived Stem Cell Therapy for Diabetic Kidney Disease Phase 1
Completed NCT04549324 - Sleep Apnea, Coronary Atherosclerosis and Heart Failure in Diabetes Patients With Nephropathy
Recruiting NCT03502031 - Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy Phase 4
Completed NCT03681704 - the Integrated Traditional Chinese and Western Medicine Treat Early Stage DKD Phase 1
Completed NCT03681249 - the Integrated Traditional Chinese and Western Medicine Treat Middle Stage DKD Early Phase 1
Withdrawn NCT03504566 - Rotation for Optimal Targeting of Albuminuria and Treatment Evaluation (ROTATE-2) Phase 4
Completed NCT03889236 - Dietary Interventions on Glycocalyx Dimensions in South Asian Patients With Diabetic Nephropathy. N/A
Completed NCT06326034 - Impact of Dapagliflozin as Add-on Therapy on Glycemic Status and Quality of Life in Type 2 Diabetic Patients Phase 4
Recruiting NCT04931537 - Screening and Application Research of Early Diabetic Nephropathy Markers Based on Lipidomics.
Recruiting NCT03622762 - Green Tea Extract on Soluble RAGE in Patients With Diabetic Nephropathy Phase 2
Recruiting NCT03445247 - Extracorporeal Low-intensity Shockwave in Diabetic Nephropathy N/A
Not yet recruiting NCT06068439 - Study of the Protective Effect of Low-dose Aspirin on Renal Function in Patients With Early Diabetic Nephropathy Phase 2/Phase 3
Recruiting NCT04143412 - Efficacy of ACE Inhibitors, MRAs and ACE Inhibitor/ MRA Combination Phase 2
Not yet recruiting NCT06222476 - Effect of Dorzagliatin on Renal Function Outcomes in People With Type 2 Diabetes: a Multicentric, Prospective, Randomized Study. N/A
Completed NCT05487755 - Investigational and Comparative Study in the Management of Diabetic Nephropathy Phase 3
Active, not recruiting NCT04573920 - Atrasentan in Patients With Proteinuric Glomerular Diseases Phase 2
Recruiting NCT05888909 - Multidimensional Accurate Diagnosis and Treatment Technology and Clinical Transformation of Type 2 Diabetes Nephropathy
Not yet recruiting NCT04962399 - Relationship Between Serum N/OFQ and Type 2 Diabetic Nephropathy
Not yet recruiting NCT03591939 - T-regulatory Cells in Diabetic Type Two Nephropathy
Active, not recruiting NCT03859817 - Observational Study to Evaluate the Relationship Between Ketonemia and Renal Function in the Diabetic Patient